EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access

Treatment of New World Mucosal Leishmaniasis: Randomized Comparison of Glucantime®, Liposomal Amphotericin B, and Miltefosine

Jaime Soto, Paula Soto, David Paz, Daniela Rivero, Martha Sánchez, Maria Arteaga, Jonathan Berman

The American Journal of Tropical Medicine and Hygiene · 2026

DOI: 10.4269/ajtmh.25-0619 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The American Journal of Tropical Medicine and Hygiene, 2026. Verfasst von Jaime Soto und 6 weiteren Autor:innen. Beteiligte Einrichtung: FUNDERMA (Fundación Nacional de Dermatología), Santa Cruz, Bolivia. Hauptthemen laut MEDLINE: Amphotericin B, Phosphorylcholine, Antiprotozoal Agents, Leishmaniasis, Mucocutaneous. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New World Mucosal Leishmaniasis (ML) is predominantly caused by Leishmania braziliensis. We performed the first randomized trial of the three recommended agents for this disease—intravenous pentavalent antimony (Sb), intravenous liposomal amphotericin B (LAMB), oral miltefosine—with 24-month follow-up. Upon study enrollment, disease was scored by the number of sites (oro–nasal–palate, pharynx, larynx) and degree of disease at each site (maximum score = 60.) Our criterion for “cure” was ≥90% diminution in the enrollment score. Cure rates were 20/40 (50%) for Sb, 18/40 (45%) for LAMB, and 23/40 (57%) for miltefosine. Cure was highly dependent on whether the patient was being treated for the first time (39/55 = 71% cure) or undergoing repeat treatment (22/63 = 35% cure). The primary reason for the low cure rate for repeat patients was laryngeal disease at enrollment. For all patients, naïve patients, and repeat patients, the miltefosine cure rate was highest but not statistically so. A curative score at 2–6 months of follow-up had a predictive value of 94% for cure. It is notable that 14 of the 57 treatment failures (25%) were attributable to relapses occurring more than 24 months after therapy completion. Myalgias/arthralgias/general bodily discomfort occurred for LAMB and Sb patients; diarrhea and motion sickness occurred for miltefosine patients; Electrocardiogram abnormalities (occasionally severe) were seen in LAMB and Sb patients. When choosing a treatment of a ML patient, cure rates in part based on disease location and absence/presence of previous treatment, route of administration, tolerability, and cost should be considered. Patients should be followed for ≥2 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amphotericin BPhosphorylcholineAntiprotozoal AgentsLeishmaniasis, MucocutaneousMeglumineOrganometallic CompoundsHumansFemaleMaleMeglumine AntimoniateAdultAdolescentMiddle AgedTreatment OutcomeYoung AdultChild

Substanzen

Amphotericin BmiltefosinePhosphorylcholineliposomal amphotericin BAntiprotozoal AgentsMeglumine AntimoniateMeglumineOrganometallic Compounds

Autor:innen und Institutionen

  • FUNDERMA (Fundación Nacional de Dermatología), Santa Cruz, Bolivia.
  • Hospital Dermatologico De Jorochito, Santa Cruz, Bolivia.
  • DermaLáser, Santa Cruz, Bolivia.
  • Práctica privada, Santa Cruz, Bolivia.
  • AB Foundation, North Bethesda, Maryland, USA.

Zitieren

APA

Soto, J., Soto, P., Paz, D., Rivero, D., Sánchez, M., Arteaga, M., & Berman, J. (2026). Treatment of New World Mucosal Leishmaniasis: Randomized Comparison of Glucantime®, Liposomal Amphotericin B, and Miltefosine. The American Journal of Tropical Medicine and Hygiene. https://doi.org/10.4269/ajtmh.25-0619

Vancouver

Soto J, Soto P, Paz D, Rivero D, Sánchez M, Arteaga M, et al. Treatment of New World Mucosal Leishmaniasis: Randomized Comparison of Glucantime®, Liposomal Amphotericin B, and Miltefosine. The American Journal of Tropical Medicine and Hygiene. 2026. doi:10.4269/ajtmh.25-0619

BibTeX
@article{Soto2026,
  author = {Soto, Jaime and Soto, Paula and Paz, David and Rivero, Daniela and Sánchez, Martha and Arteaga, Maria and Berman, Jonathan},
  title = {Treatment of New World Mucosal Leishmaniasis: Randomized Comparison of Glucantime®, Liposomal Amphotericin B, and Miltefosine},
  journal = {The American Journal of Tropical Medicine and Hygiene},
  year = {2026},
  doi = {10.4269/ajtmh.25-0619}
}
Kostenlos starten →